|
1
|
Pandarathodiyil AK and Sivapathasundharam
B: Diagnostic challenges of superficial mucoceles: An update. J
Oral Maxillofac Pathol. 27:616–621. 2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hober C, Fredeau L, Pham-Ledard A, Boubaya
M, Herms F, Celerier P, Aubin F, Beneton N, Dinulescu M, Jannic A,
et al: Cemiplimab for Locally Advanced and Metastatic Cutaneous
Squamous-Cell Carcinomas: Real-Life Experience from the French
CAREPI Study Group. Cancers (Basel). 13(3547)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bray ER, Lin RR, Li JN, Elgart GW, Elman
SA and Maderal AD: Immune checkpoint inhibitor associated epidermal
necrosis, beyond SJS and TEN: A review of 98 cases. Arch Dermatol
Res. 316(233)2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lin M, Gong T, Ruan S, Lv X, Chen R, Su X,
Cheng B and Ji C: Emerging insights into stevens-johnson syndrome
and toxic epidermal necrolysis induced by immune checkpoint
inhibitor and tumor-targeted therapy. J Inflamm Res. 17:2337–2351.
2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Amy DPB, Shalabi A, Finfter O, Birenzweig
Y and Zadik Y: Severe chronic nonlichenoid oral mucositis in
pembrolizumab-treated patients: New cases and a review of the
literature. Immunotherapy. 12:777–784. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Elad S, Yarom N, Zadik Y, Kuten-Shorrer M
and Sonis ST: The broadening scope of oral mucositis and oral
ulcerative mucosal toxicities of anticancer therapies. CA Cancer J
Clin. 72:57–77. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Srivastava A, Nogueras-Gonzalez GM, Geng
Y, Singh J, Myers JN, Li Y and Chambers MS: Oral toxicities
associated with immune checkpoint inhibitors: Meta-analyses of
clinical trials. J Immunother Precis Oncol. 7:24–40.
2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Heguedusch D, Tomo S, Almeida OP and Alves
FA: Superficial mucoceles in cancer patients: A retrospective
series from a Stomatology unit. Med Oral Patol Oral Cir Bucal.
28:e562–e566. 2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Salati M, Pifferi M, Baldessari C,
Bertolini F, Tomasello C, Cascinu S and Barbieri F: Stevens-Johnson
syndrome during nivolumab treatment of NSCLC. Ann Oncol.
29:283–284. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gracia-Cazaña T, Padgett E, Calderero V
and Oncins R: Nivolumab-associated Stevens-Johnson syndrome in a
patient with lung cancer. Dermatol Online J.
27(13030/qt2897t6dq)2021.PubMed/NCBI
|
|
11
|
Pîrlog CF, Paroșanu AI, Slavu CO, Olaru M,
Popa AM, Iaciu C, Niță I, Moțatu P, Horia C, Manolescu LSC and
Nițipir C: Nivolumab hypersensitivity reactions a Myth or reality
in solid tumors-a systematic review of the literature. Curr Oncol.
29:9428–9436. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shah KM, Rancour EA, Al-Omari A and
Rahnama-Moghadam S: Striking enhancement at the site of radiation
for nivolumab-induced Stevens-Johnson syndrome. Dermatol Online J.
24(13030/qt97g3t63v)2018.PubMed/NCBI
|
|
13
|
Dasanu CA: Late-onset Stevens-Johnson
syndrome due to nivolumab use for hepatocellular carcinoma. J Oncol
Pharm Pract. 25:2052–2055. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ito J, Fujimoto D, Nakamura A, Nagano T,
Uehara K, Imai Y and Tomii K: Aprepitant for refractory
nivolumab-induced pruritus. Lung Cancer. 109:58–61. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chirasuthat P and Chayavichitsilp P:
Atezolizumab-Induced stevens-johnson syndrome in a patient with
non-small cell lung carcinoma. Case Rep Dermatol. 10:198–202.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hammond S, Olsson-Brown A, Gardner J,
Thomson P, Ali SE, Jolly C, Carr D, Ressel L, Pirmohamed M and
Naisbitt D: T cell mediated hypersensitivity to previously
tolerated iodinated contrast media precipitated by introduction of
atezolizumab. J Immunother Cancer. 9(e002521)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Saw S, Lee HY and Ng QS:
Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma
patients. Eur J Cancer. 81:237–239. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liniker E, Menzies AM, Kong BY, Cooper A,
Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, et
al: Activity and safety of radiotherapy with anti-PD-1 drug therapy
in patients with metastatic melanoma. Oncoimmunology.
5(e1214788)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sandhu M, Kc B, Bhandari J, Gambhir HS and
Farah R: Pembrolizumab-associated stevens-johnson syndrome in a
patient with metastatic non-small cell lung cancer: A case report.
Cureus. 15(e41439)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Riano I, Cristancho C and Treadwell T:
Stevens-Johnson syndrome-like reaction after exposure to
pembrolizumab and recombinant zoster vaccine in a patient with
metastatic lung cancer. J Investig Med High Impact Case Rep.
8(2324709620914796)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Machida M, Yamazaki C, Kouda N, Hanai Y,
Sato H, Konda A, Yamagata Y, Itho T and Aisaka H: A case report
involving suppressed nuclear receptor transcription factors 4a1 and
Stevens-Johnson syndrome induced by a single dose of pembrolizumab
and successfully treated with early steroid administration,
resulting in complete remission of stage III lung cancer. J Pharm
Health Care Sci. 8(29)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wu JY, Kang K, Yi J and Yang B:
Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous
cell carcinoma of the lung: A case report and review of literature.
World J Clin Cases. 10:6110–6118. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lopez M, Hagopian G, Doan L, Lee BJ, Rojek
NW, Smith J, Ou SI, Demirdag YY and Nagasaka M: Osimertinib
tolerance in a patient with Stevens Johnson syndrome during
osimertinib therapy after treatment with pembrolizumab. Allergy
Asthma Clin Immunol. 19(93)2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Haratake N, Tagawa T, Hirai F, Toyokawa G,
Miyazaki R and Maehara Y: Stevens-Johnson syndrome induced by
pembrolizumab in a lung cancer patient. J Thorac Oncol.
13:1798–1799. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gianni C, Bronte G, Delmonte A, Burgio MA,
Andrikou K, Monti M, Menna C, Frassineti GL and Crinò L: Case
Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by
Osimertinib Sequential to Pembrolizumab in a Patient With
EGFR-Mutated Lung Adenocarcinoma. Front Pharmacol.
12(672233)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Godfrey H, Jedlowski P and Thiede R:
Severe cutaneous adverse reactions associated with the immune
checkpoint inhibitors: A case/non-case analysis using the Food and
Drug Administration Adverse Event Reporting System. Australas J
Dermatol. 65:243–253. 2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hwang A, Iskandar A and Dasanu CA:
Stevens-Johnson syndrome manifesting late in the course of
pembrolizumab therapy. J Oncol Pharm Pract. 25:1520–1522.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhang J, Zhang P, Xu QY, Zhu YT, Chen W
and Ji C: Pembrolizumab associated Stevens-Johnson syndrome with
porokeratosis in a patient in the setting of primary hepatocellular
carcinoma. Australas J Dermatol. 63:e71–e74. 2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kamei J, Yokoyama H, Niki T, Suda R,
Sugihara T, Fujisaki A, Ando S, Iwami D and Fujimura T: Complete
response to pembrolizumab for metastatic urothelial carcinoma in
the renal pelvis of allograft kidney. IJU Case Rep. 5:199–202.
2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Li X, Lei Y, Liu J, Lin H, Chen K, Yin F,
Wang C and Zhang H: Case report: A successful treatment with immune
checkpoint inhibitors was associated with severe dermatologic
toxicities in a patient with double primary malignancies. Discov
Oncol. 14(146)2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Dika E, Ravaioli GM, Fanti PA, Piraccini
BM, Lambertini M, Chessa MA, Baraldi C, Ribero S, Andrea A, Melotti
B and Patrizi A: Cutaneous adverse effects during ipilimumab
treatment for metastatic melanoma: A prospective study. Eur J
Dermatol. 27:266–270. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Alexandris D, Alevizopoulos N, Gakiopoulou
H, Stavrinou N and Vourlakou C: Cutaneous Stevens Johnson-Toxic
Epidermal Necrolysis Immunotherapy related Toxicities in Lung
Cancer Patients. J Oncol Pharm Pract. 28:1276–1282. 2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Rouyer L, Bursztejn AC, Charbit L, Schmutz
JL and Moawad S: Stevens-Johnson syndrome associated with radiation
recall dermatitis in a patient treated with nivolumab. Eur J
Dermatol. 28:380–381. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ryu S, Jun I, Kim TI, Seo KY and Kim EK:
Pembrolizumab-induced stevens-johnson syndrome with severe ocular
complications. Ocul Immunol Inflamm. 30:1533–1535. 2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Rodríguez-Otero N, Chamorro-Pérez J,
Fernández-Lozano C, Elías-Sáenz I, Berná-Rico E, de Nicolás-Ruanes
B, Meléndez-Gispert MR, Moreno-García Del Real C, Martínez-Botas J,
Cortés-Salgado A and Solano-Solares E: Nivolumab-induced
Stevens-Johnson syndrome: not only due to PD-1 inhibition. J
Allergy Clin Immnol Pract. 11:2936–2938.e1. 2023.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Goldinger SM, Stieger P, Meier B,
Micaletto S, Contassot E, French LE and Dummer R: Cytotoxic
cutaneous adverse drug reactions during Anti-PD-1 therapy. Clin
Cancer Res. 22:4023–4029. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Pierre AB, Jernigan AM and Castellano T:
SJS/TEN immune-related dermatologic reaction secondary to immune
checkpoint inhibitor pembrolizumab in skin of color. Gynecol Oncol
Rep. 50(101290)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Robinson S, Saleh J, Curry J and Mudaliar
K: Pembrolizumab-Induced stevens-johnson syndrome/toxic epidermal
necrolysis in a patient with metastatic cervical squamous cell
carcinoma: A case report. Am J Dermatopathol. 42:292–296.
2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Saad E, Adhikari P, Antala D, Abdulrahman
A, Begiashvili V, Mohamed K, Ali E and Zhang Q: Steven-Johnson
Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a
Patient With Metastatic Gastric Adenocarcinoma. J Med Cases.
13:449–455. 2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Cao J, Li Q, Zhi X, Yang F, Zhu W, Zhou T,
Hou X and Chen D: Pembrolizumab-induced autoimmune Stevens-Johnson
syndrome/toxic epidermal necrolysis with myositis and myocarditis
in a patient with esophagogastric junction carcinoma: A case
report. Transl Cancer Res. 10:3870–3876. 2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Oguri T, Sasada S, Shimizu S, Shigematsu
R, Tsuchiya Y, Ishioka K, Takahashi S, Oki K, Kimura Y, Seki R, et
al: A case of guillain-barré syndrome and stevens-johnson
syndrome/toxic epidermal necrosis overlap after pembrolizumab
treatment. J Investig Med High Impact Case Rep.
9(23247096211037462)2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Maloney NJ, Ravi V, Cheng K, Bach DQ and
Worswick S: Stevens-Johnson syndrome and toxic epidermal
necrolysis-like reactions to checkpoint inhibitors: A systematic
review. Int J Dermatol. 59:e183–e188. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Nayar N, Briscoe K and Fernandez Penas P:
Toxic epidermal necrolysis-like reaction with severe satellite cell
necrosis associated with nivolumab in a patient with ipilimumab
refractory metastatic melanoma. J Immunother. 39:149–152.
2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Vivar KL, Deschaine M, Messina J, Divine
JM, Rabionet A, Patel N, Harrington MA and Seminario-Vidal L:
Epidermal programmed cell death-ligand 1 expression in TEN
associated with nivolumab therapy. J Cutan Pathol. 44:381–384.
2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Koshizuka K, Sakurai D, Sunagane M, Mita
Y, Hamasaki S, Suzuki T, Kikkawa N, Nakano M and Hanazawa T: Toxic
epidermal necrolysis associated with nivolumab treatment for head
and neck cancer. Clin Case Rep. 9:848–852. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Pintea I, Petricau C, Dumitrascu D,
Muntean A, Branisteanu DC, Branisteanu DE and Deleanu D:
Hypersensitivity reactions to monoclonal antibodies: Classification
and treatment approach (Review). Exp Ther Med.
22(949)2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Basu P, Tong Y, Hinds BR and Schneider JA:
Nivolumab-induced toxic epidermal necrolysis with retiform purpura.
Br J Dermatol. 183(e32)2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Keerty D, Koverzhenko V, Belinc D, LaPorta
K and Haynes E: Immune-Mediated toxic epidermal necrolysis. Cureus.
12(e9587)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Kim MC and Khan HN: Nivolumab-Induced
toxic epidermal necrolysis: Rare but fatal complication of immune
checkpoint inhibitor therapy. Cureus. 13(e15017)2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Griffin LL, Cove-Smith L, Alachkar H,
Radford JA, Brooke R and Linton KM: Toxic epidermal necrolysis
(TEN) associated with the use of nivolumab (PD-1 inhibitor) for
lymphoma. JAAD Case Rep. 4:229–231. 2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Gopee NH, Gourley AM, Oliphant TJ and
Hampton PJ: Toxic epidermal necrolysis occurring with immune
checkpoint inhibitors. Dermatol Online J.
26(13030/qt8fc428f6)2020.PubMed/NCBI
|
|
52
|
Gallo Marin B, Oliva R, Kahn B, Borgovan
T, Brooks BE and Massoud CM: Pembrolizumab-induced Toxic Epidermal
Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
R I Med J (2013). 105:34–36. 2022.PubMed/NCBI
|
|
53
|
Neema S, Sathu S, Vasudevan B, Shreshta S,
Bhatt S and K L: Pembrolizumab-induced toxic epidermal necrolysis:
A rare cause of severe adverse drug reaction. Indian J Dermatol
Venereol Leprol. 89:589–591. 2023.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Kian W, Zemel M, Elobra F, Sharb AA,
Levitas D, Assabag Y, Alguayn F, Yakobson A, Rouvinov K and Fuchs
L: Intravenous immunoglobulin efficacy on pembrolizumab induced
severe toxic epidermal necrolysis. Anticancer Drugs. 33:e738–e740.
2022.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Eldani C, Darrigade AS, Beylot-Barry M,
Jullie ML, Ducharme O, Milpied B and Pham-Ledard A: Successful
rechallenge for severe lichenoid drug reaction to pembrolizumab
presenting as ‘toxic epidermal necrolysis-like’. Eur J Dermatol.
32:805–807. 2022.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Borg L, Buhagiar M, La Ferla E, Pisani D,
Said J and Boffa MJ: Pembrolizumab-Induced Toxic Epidermal
Necrolysis. Case Rep Oncol. 15:887–893. 2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Chow KVC, O'Leary C, Paxton-Hall F, Lambie
D and O'Byrne K: Pembrolizumab-induced toxic epidermal necrolysis:
Case report. Oxf Med Case Reports. 2022(omac025)2022.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Cai ZR, Lecours J, Adam JP, Marcil I,
Blais N, Dallaire M, Belisle A and Mathieu A: Toxic epidermal
necrolysis associated with pembrolizumab. J Oncol Pharm Pract.
26:1259–1265. 2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Schwartz LH, Litière S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-Update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016.PubMed/NCBI View Article : Google Scholar
|
|
60
|
US Department of Health and Human
Services: Common terminology criteria for adverse events (CTCAE)
version 5.0. National Institutes of Health, National Cancer
Institute, 2017.
|
|
61
|
Yang A, Xuan R, Melbourne W, Tran K and
Murrell DF: Validation of the BIOCHIP test for the diagnosis of
bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus. J
Eur Acad Dermatol Venereol. 34:153–160. 2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Ellis SR, Vierra AT, Millsop JW, Lacouture
ME and Kiuru M: Dermatologic toxicities to immune checkpoint
inhibitor therapy: A review of histopathologic features. J Am Acad
Dermatol. 83:1130–1143. 2020.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Teng YS and Yu S: Molecular mechanisms of
cutaneous immune-related adverse events (irAEs) induced by immune
checkpoint inhibitors. Curr Oncol. 30:6805–6819. 2023.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Reike MJ, Bahlburg H, Brehmer M, Berg S,
Noldus J, Roghmann F, Bach P and Tully KH: Side effects of
drug-antibody conjugates enfortumab-vedotin and
sacituzumab-govitecan in targeted therapy in cancer. Cancer
Epidemiol. 90(102574)2024.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Lacouture ME, Patel AB, Rosenberg JE and
O'Donnell PH: Management of dermatologic events associated with the
Nectin-4-directed antibody-drug conjugate enfortumab vedotin.
Oncologist. 27:e223–e232. 2022.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Xia C, Jiang C, Li W, Wei J, Hong H, Li J,
Feng L, Wei H, Xin H and Chen T: A phase II Randomized clinical
trial and mechanistic studies using improved probiotics to prevent
oral mucositis induced by concurrent radiotherapy and chemotherapy
in nasopharyngeal carcinoma. Front Immunol.
12(618150)2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Pulito C, Cristaudo A, Porta C, Zapperi S,
Blandino G, Morrone A and Strano S: Oral mucositis: The hidden side
of cancer therapy. J Exp Clin Cancer Res. 39(210)2020.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Maria OM, Eliopoulos N and Muanza T:
Radiation-Induced oral mucositis. Front Oncol. 7(89)2017.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Radochová V, Šembera M, Slezák R, Heneberk
O and Radocha J: Oral Mucositis association with periodontal
status: A retrospective analysis of 496 patients undergoing
hematopoietic stem cell transplantation. J Clin Med.
10(5790)2021.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Lacouture M and Sibaud V: Toxic side
effects of targeted therapies and immunotherapies affecting the
skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 19 (Suppl
1):S31–S39. 2018.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Vigarios E, Epstein JB and Sibaud V: Oral
mucosal changes induced by anticancer targeted therapies and immune
checkpoint inhibitors. Support Care Cancer. 25:1713–1739.
2017.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Klein BA, Alves FA, de Santana Rodrigues
Velho J, Vacharotayangul P, Hanna GJ, LeBoeuf NR, Shazib MA, Villa
A, Woo SB, Sroussi H, et al: Oral manifestations of immune-related
adverse events in cancer patients treated with immune checkpoint
inhibitors. Oral Dis. 28:9–22. 2022.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Lloyd-Lavery A, Hodgson T, Coupe N, Bond
S, Shah K, Espinosa O, Payne MJ, Middleton MR and Matin RN: Delayed
oral toxicity from long-term vemurafenib therapy. Br J Dermatol.
174:1159–1160. 2016.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Shephard MK and Lloyd-Lavery A: Resolution
of severe oral mucosal changes related to vemurafenib therapy with
intensive periodontal treatment. Br J Dermatol. 181:639–640.
2019.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Pileri A, Cricca M, Gandolfi L, Misciali
C, Casadei B, Zinzani PL and Patrizi A: Vemurafenib mucosal
side-effect. J Eur Acad Dermatol Venereol. 30:1053–1055.
2016.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Prado-Ribeiro AC, Santos-Silva AR, Faria
KM, Silva WG, Simonato LE, Moutinho K and Brandão TB:
Radiation-related superficial oral mucoceles: An under-recognized
acute toxicity in head and neck cancer patients. Med Oral Patol
Oral Cir Bucal. 23:e518–e523. 2018.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Campana F, Sibaud V, Chauvel A, Boiron JM,
Taieb A and Fricain JC: Recurrent superficial mucoceles associated
with lichenoid disorders. J Oral Maxillofac Surg. 64:1830–1833.
2006.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Demarosi F, Lodi G, Carrassi A and
Sardella A: Superficial oral mucoceles: Description of two cases in
patients with graft-versus-host disease. J Otolaryngol. 36:E76–E78.
2007.PubMed/NCBI
|
|
79
|
Balasubramaniam R, Alawi F and DeRossi S:
Superficial mucoceles in chronic graft-versus-host disease: A case
report and review of the literature. Gen Dent. 57:82–88.
2009.PubMed/NCBI
|
|
80
|
García-F-Villalta MJ, Pascual-López M,
Elices M, Daudén E, García-Diez A and Fraga J: Superficial
mucoceles and lichenoid graft versus host disease: report of three
cases. Acta Derm Venereol. 82:453–455. 2002.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Brooks JK, Schwartz KG and Basile JR:
Superficial mucocele of the ventral tongue: Presentation of a rare
case and literature review. J Oral Maxillofac Surg. 74:1175–1179.
2016.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Masri BA, Perry LM and Stoopler ET:
Palatal superficial mucoceles associated with chronic
graft-versus-host disease. Hematol Transfus Cell Ther.
45(140)2023.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Deutsch A and McLellan BN: Topical
tacrolimus for refractory superficial mucoceles in a patient with
chronic graft versus host disease. JAAD Case Rep. 6:426–427.
2020.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Nicolatou-Galitis O, Kitra V, Van
Vliet-Constantinidou C, Peristeri J, Goussetis E, Petropoulos D and
Grafakos S: The oral manifestations of chronic graft-versus-host
disease (cGVHD) in paediatric allogeneic bone marrow transplant
recipients. J Oral Pathol Med. 30:148–153. 2001.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Zadik Y, Keshet N and Aframian DJ: Oral
superficial mucocele in cancer patients. Oral Oncol. 56:e15–e16.
2016.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Pengpis N, Prueksrisakul T and
Chanswangphuwana C: Clinical characteristics of oral chronic
graft-versus-host disease according to the 2014 National Institutes
of Health (USA) consensus criteria. Med Oral Patol Oral Cir Bucal.
28:e167–e173. 2023.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Elad S, Zadik Y and Yarom N: Oral
complications of nonsurgical cancer therapies. Atlas Oral
Maxillofac Surg. Clin. North Am. 25:133–147. 2017.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Eveson JW: Superficial mucoceles: Pitfall
in clinical and microscopic diagnosis. Oral Surg Oral Med Oral
Pathol. 66:318–322. 1988.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Rather S, Shah AA, Shah FY, Kaur S, Bhat
MA, Reyaz S and Hassan I: Dermoscopy of oral mucosal lesions:
experience from a tertiary care center in north india and review of
literature. Indian Dermatol Online J. 13:346–360. 2022.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Ayhan E, Toprak SF, Kaya Ş and Akkaynak Ş:
Dermoscopy of oral mucocele: Three types of extravasation
mucoceles. Turk J Med Sci. 50:96–102. 2020.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Kumar Jha A, Vinay K, Sławińska M,
Sonthalia S, Sobjanek M, Kamińska-Winciorek G, Errichetti E, Kamat
D, Chatterjee D, Apalla Z, et al: Application of mucous membrane
dermoscopy (mucoscopy) in diagnostics of benign oral
lesions-literature review and preliminary observations from
International Dermoscopy Society study. Dermatol Ther.
34(e14478)2021.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Manfredini M, Pedroni G, Bigi L, Apponi R,
Murri Dello Diago A, Dattola A, Farnetani F and Pellacani G:
Acquired white oral lesions with specific patterns: Oral lichen
planus and lupus erythematosus. Dermatol Pract Concept.
11(e2021074)2021.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Venugopal DC, Warrier SA, S E, H T and
Ramesh P: Superficial Mucocele: A Rare Presentation. Cureus.
13(e18038)2021.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Płatkowska A, Słowińska M, Zalewska J,
Swacha Z, Szumera-Ciećkiewicz A, Wągrodzki M, Patera J,
Łapieńska-Rey K, Lorent M, Ługowska I, et al: Minimally Invasive
plasma device management of multiple benign skin cancers associated
with rare genodermatoses-case series and review of the therapeutic
methods. J Clin Med. 13(4377)2024.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Holcomb JD, Kalhan R and Pilcher B:
Evaluation of skin tissue effects from treatment with a novel
hand-held plasma energy device. J Cosmet Dermatol. 21:1998–2004.
2022.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Bell A and Kasi A: Oral Mucositis. In:
StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL,
2024.
|
|
97
|
National Library of Medicine:
Stomatitides. https://www.ncbi.nlm.nih.gov/medgen/52511.
|
|
98
|
Lee JH, Lee JH, Lee JH, Kim SY and Kim GM:
Case of sunitinib-induced Stevens-Johnson syndrome. J Dermatol.
40:753–754. 2013.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Gronich N, Maman D, Stein N and Saliba W:
Culprit medications and risk factors associated with
stevens-johnson syndrome and toxic epidermal necrolysis:
Population-Based nested case-control study. Am J Clin Dermatol.
23:257–266. 2022.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Vinay K, Yanamandra U, Dogra S, Handa S,
Suri V, Kumari S, Khadwal A, Prakash G, Lad D, Varma S and Malhotra
P: Long-term mucocutaneous adverse effects of imatinib in Indian
chronic myeloid leukemia patients. Int J Dermatol. 57:332–338.
2018.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Yang S, Wu L, Li X, Huang J, Zhong J and
Chen X: Crizotinib-associated toxic epidermal necrolysis in an
ALK-positive advanced NSCLC patient. Mol Clin Oncol. 8:457–459.
2018.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Koizumi T, Fukushima T, Tatai T, Kobayashi
T, Sekiguchi N, Sakamoto A and Sasaki S: Successful treatment of
crizotinib-induced dysgeusia by switching to alectinib in
ALK-positive non-small cell lung cancer. Lung Cancer. 88:112–113.
2015.PubMed/NCBI View Article : Google Scholar
|
|
103
|
European Medicines Agency: ANNEX I:
Summary of product characteristics: MabThera. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf.
|
|
104
|
Patrizi A, Venturi M, Dika E, Maibach H,
Tacchetti P and Brandi G: Cutaneous adverse reactions linked to
targeted anticancer therapies bortezomib and lenalidomide for
multiple myeloma: New drugs, old side effects. Cutan Ocul Toxicol.
33:1–6. 2014.PubMed/NCBI View Article : Google Scholar
|
|
105
|
European Medicines Agency: ANNEX I:
Summary of product characteristics: velcade. https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf.
|
|
106
|
Villa A and Kuten-Shorrer M: Pathogenesis
of Oral Toxicities Associated with Targeted Therapy and
Immunotherapy. Int J Mol Sci. 24(8188)2023.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Kurian CJ, Desai A, Rafferty W and Abou
Hussein AK: Case report: Alpelisib-induced Stevens-Johnson
syndrome. Front Oncol. 12(954027)2022.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Nunnery SE and Mayer IA: Management of
toxicity to isoform α-specific PI3K inhibitors. Ann Oncol. 30
(Suppl_10):x21–x26. 2019.PubMed/NCBI View Article : Google Scholar
|
|
109
|
European Medicines Agency: ANNEX I:
Summary of product characteristics: Piqray. https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf.
|
|
110
|
Vigarios E, Beylot-Barry M, Jegou MH,
Oberic L, Ysebaert L and Sibaud V: Dose-limiting stomatitis
associated with ibrutinib therapy: A case series. Br J Haematol.
185:784–788. 2019.PubMed/NCBI View Article : Google Scholar
|
|
111
|
European Medicines Agency: ANNEX I:
Summary of product characteristics: imbruvica. https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_en.pdf.
|
|
112
|
European Medicines Agency: ANNEX I:
Summary of product characteristics: venclyxto. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf.
|
